Bilaçeroğlu Semra
University of Health Sciences-Turkey, Izmir Dr. Suat Seren Training and Research Hospital for Thoracic Medicine and Surgery, Izmir, Turkey.
J Thorac Dis. 2020 Dec;12(12):7598-7606. doi: 10.21037/jtd-2019-thym-14.
Pathologic diagnosis of thymic tumors (TTs) can be made by surgical or nonsurgical procedures. About 20% of TTs had been diagnosed by pretreatment biopsy methods while the rest had gone to surgery for diagnosis and treatment. However, in the last two decades there was an increase in pretreatment procedures for optimal management of locally advanced or metastatic TTs. Pretreatment tissue diagnosis of a noninvasive TT is not a standard option but is required if there is suspect or atypical clinical presentation and imaging, an invasive tumor requiring a nonsurgical approach or preoperative chemotherapy or chemo-radiotherapy, strong possibility of lymphoma or unclear differential diagnosis between lymphoma or other solid tumor by imaging studies, or suspicion of a metastatic lesion. In surgical diagnosis anterior mediastinotomy, video-assisted thoracic surgery or mediastinoscopy can be chosen for invasive TTs whereas total resection is performed for small, noninvasive tumors. Nonsurgical diagnosis can be made by transthoracic fine or core needle biopsies (TTFNA, TTCNB), conventional bronchoscopy, endobronchial ultrasonography-guided transbronchial needle aspiration (EBUS-TBNA), endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) or medical thoracoscopy depending on procedural amenability according to tumor extension. TTFNA and TTCNB have been the most frequently used nonsurgical methods. However, there is an upward trend in using conventional bronchoscopy, EBUS-TBNA, EUS-FNA and medical thoracoscopy recently. To increase the diagnostic performance of these procedures in TTs, recommendations are (I) obtaining histologic specimens, (II) combining smears or liquid based cytology preparations and cell blocks, (III) obtaining multiple sufficient samples, (IV) combining histologic and cytologic specimens, (V) performing morphologic, immunohistochemical and molecular analyses on all specimens, (VI) using rapid onsite evaluation for cytologic specimens, (VII) correlating pathologic, clinical and radiologic findings, (VIII) consulting experienced pathologists.
胸腺肿瘤(TTs)的病理诊断可通过手术或非手术方法进行。约20%的TTs通过预处理活检方法确诊,其余则通过手术进行诊断和治疗。然而,在过去二十年中,为了对局部晚期或转移性TTs进行最佳管理,预处理程序有所增加。非侵袭性TTs的预处理组织诊断并非标准选择,但如果存在可疑或非典型临床表现及影像学表现、需要非手术方法或术前化疗或放化疗的侵袭性肿瘤、淋巴瘤可能性大或影像学研究难以鉴别淋巴瘤与其他实体瘤、或怀疑有转移灶,则需要进行预处理组织诊断。在手术诊断中,对于侵袭性TTs可选择前纵隔切开术、电视辅助胸腔镜手术或纵隔镜检查,而对于小的非侵袭性肿瘤则进行完整切除。非手术诊断可通过经胸细针或粗针活检(TTFNA、TTCNB)、传统支气管镜检查、支气管内超声引导经支气管针吸活检(EBUS-TBNA)、内镜超声引导细针穿刺活检(EUS-FNA)或内科胸腔镜检查进行,具体取决于根据肿瘤范围的操作可行性。TTFNA和TTCNB是最常用的非手术方法。然而,最近传统支气管镜检查、EBUS-TBNA、EUS-FNA和内科胸腔镜检查的使用呈上升趋势。为提高这些程序对TTs的诊断性能,建议如下:(I)获取组织学标本;(II)将涂片或液基细胞学标本与细胞块相结合;(III)获取多个足够的样本;(IV)将组织学和细胞学标本相结合;(V)对所有标本进行形态学、免疫组织化学和分子分析;(VI)对细胞学标本进行快速现场评估;(VII)将病理、临床和影像学结果相关联;(VIII)咨询经验丰富的病理学家。